8 research outputs found
New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders
© 2020, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Purpose of Review: This paper aims to review novel trends in cholinergic neuroimaging in Alzheimer and Lewy body parkinsonian disorders. Recent Findings: The spectrum of cholinergic imaging is expanding with the availability of spatially more precise radioligands that allow assessment of previously less recognized subcortical and cortical structures with more dense cholinergic innervation. In addition, advances in MRI techniques now allow quantitative structural or functional assessment of both the cholinergic forebrain and the pedunculopontine nucleus, which may serve as non-invasive prognostic predictors. Multimodal imaging approaches, such as PET-MRI or multiligand PET, offer new insights into the dynamic and interactive roles of the cholinergic system at both local and larger-scale neural network levels. Summary: Our understanding of the heterogeneous roles of the cholinergic system in age-related diseases is evolving. Multimodal imaging approaches that provide complimentary views of the cholinergic system will be necessary to shed light on the impact of cholinergic degeneration on regional and large-scale neural networks that underpin clinical symptom manifestation in neurodegeneration
Possible syndrome sérotoninergique induit par l’association de tramadol à de la sertraline chez une femme âgée.
International audienc
Possible syndrome sérotoninergique induit par l’association de tramadol à de la sertraline chez une femme âgée.
International audienc
Antiparkinsoniens, troubles du sommeil, malaises, pertes de connaissance en Médecine Gériatrique aiguë.
National audienc
Evaluation d’impact sur la santé et évaluation d’impact sur l’équité en santé : éventail de pratiques et questions de recherche
Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease
Psychiatric Disorders in Dementia
Alzheimer’s disease (AD) is the most common form of dementia, a neurodegenerative disorder which is characterized not only by cognitive deterioration but also by a diversity of behavioral and psychological signs and symptoms of dementia (BPSD). BPSD in AD or other dementia subtypes such as frontotemporal dementia (FTD) or dementia with Lewy bodies (DLB) consist of delusions, hallucinations, activity disturbances, aggression/agitation, diurnal rhythm disturbances, mood disorders, apathy, and anxieties/phobias. Neuroimaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are very essential and useful imaging tools to differentially diagnose between AD and non-AD or healthy control subjects or between different dementia subtypes, such as AD and DLB or FTD. Besides their diagnostic utility, PET and SPECT are useful tools to investigate the cerebral pathophysiology of BPSD in dementia.Below, PET and SPECT neuroimaging research in dementia spanning the last three decades has been systematically reviewed. The most commonly used PET and SPECT radioligands, as well as new developments in the field, all targeting different and unique aspects of neurodegeneration, are described. Furthermore, PET and SPECT research in BPSD with a main focus on depression, apathy, and psychosis in AD, DLB, and FTD are discussed in detail. On the whole, both PET and SPECT have demonstrated that depending on the behavioral phenomenon and dementia subtype, BPSD are the fundamental expression of very regional cerebral pathological events rather than a diffuse brain illness